Posted by Michael Wonder on 15 Dec 2021
FDA approves first drug to prevent graft versus host disease
15 December 2021 - Today, the U.S. FDA approved Orencia (abatacept) for the prophylaxis of acute graft versus host disease, a condition that occurs when donor bone marrow or stem cells attack the graft recipient, in combination with certain immunosuppressants.
Orencia may be used in adults and paediatric patients two years of age or older undergoing haematopoietic stem cell transplantation (commonly known as bone marrow transplantation or stem cell transplantation) from an unrelated donor.
